Under construction – not a live service
Sign in
Taking people in AustraliaPhase 1

Tests BAY 3771249, alone or with cetuximab, in advanced colorectal cancer with KRAS G12D

Tests BAY 3771249, alone or with cetuximab, in adults with advanced colorectal cancer.

Key facts

Who runs it
Bayer
Where
Albury, Malvern, and Waratah, AustraliaSee the 3 sitesAlso in 9 other countries, 18 sites
Registry title
A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation
Status
Recruiting
Phase
Phase 1
People taking part
130 people, planned
Started
7 Apr 2026
Expected to end
9 Jul 2030
Type of study
Interventional, 2 groups
Treatments tested
  • BAY 3771249
  • Cetuximab
Record updated
5 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or metastatic colorectal cancer (adenocarcinoma of the colon or rectum) that has a KRAS G12D mutation.

Age
18 years or older (or the legal age of consent where the study takes place).
Sex
Men and women can join.
Disease stage
Advanced or metastatic adenocarcinoma of the colon or rectum, confirmed by tissue tests. At least one tumor outside the brain and spinal cord that can be measured (RECIST v1.1).
Earlier treatment
Side effects from earlier cancer treatment must have settled to Grade 1 or less. Some exceptions apply, such as hair loss and mild nerve or hormone problems.
Biomarker or test result
The tumor must have a KRAS G12D mutation.

Main reasons for not taking part

  • Cancer spread to the lining of the brain or spinal cord, or active brain metastases with symptoms
  • Known HIV infection, or active hepatitis B or hepatitis C
  • Significant heart disease or risk factors for a dangerous heart rhythm
  • History of pneumonitis or interstitial lung disease, or of keratitis (eye inflammation)
  • Another cancer in the past 3 years that is different from the one being studied

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • KRAS G12D mutated solid tumor
  • Participant must be ≥18 years old or the legal age of consent in the jurisdiction in which the study is taking place when signing the screening ICF
  • At least one measurable lesion as per RECIST v1.1. outside the CNS
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1
  • Male or Female: Contraceptive use by participant or participant's partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • Life expectancy of at least 3 months in the opinion of the Investigator
  • Histologically/pathologically documented diagnosis of advanced/metastatic adenocarcinoma of the colon and rectum
  • Adequate hematologic and end-organ function

Who cannot take part

  • Significant traumatic injury or major surgical procedure within 4 weeks of first dose of study intervention
  • Previous (within 3 years) or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in the respective substudy
  • Toxicities from prior anticancer therapy, defined as not having resolved to Grade ≤1 or as specified in the respective substudy protocol as per NCI CTCAE v.6.0 with the following exceptions: Alopecia of any grade, Peripheral neuropathy Grade ≤2, Autoimmune endocrine disorders Grade ≤2 managed with stable endocrine replacement therapy
  • Leptomeningeal disease or carcinomatous meningiti
  • Known hypersensitivity to any component of study intervention
  • Active infection requiring systemic anti-infective therapy within 14 days of first dose of study intervention
  • Known HIV infection
  • Active Hepatitis B virus (HBV) infection
  • Active Hepatitis C virus (HCV) infection
  • Significant cardiac disorder
  • Participants with inadequately managed diabetes as assessed by the Investigator
  • History of (non-infectious) pneumonitis/interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis (unless it has resolved without sequelae without use of steroids), or any evidence of clinically-active pneumonitis/ILD
  • History of the following eye disorders: keratitis, ulcerative keratitis
  • History of risk factors for torsade de pointes (TdP) (e.g., heart failure, family history of long QT syndrome)
  • Uncontrolled and/or active/symptomatic brain metastases

Where in Australia

Also in 9 other countries, 18 sites

  • Border Medical oncology - Albury Wodonga Regional Cancer CentreAlbury, AustraliaNot yet recruiting
  • Cabrini Health Oncology ResearchMalvern, AustraliaNot yet recruiting
  • Calvary Mater Hospital Newcastle - OncologyWaratah, AustraliaTaking people

About the trial

What the trial wants to find out

Researchers are looking for a better way to treat people who have advanced or metastatic colorectal cancer (CRC) with a specific mutation, the G12D mutation, in a protein called KRAS.

Read full original descriptionShow less

Colorectal cancer (CRC) is a common type of cancer that affects the large bowel (colon) or the rectum (the section at the end of the bowel). When CRC spreads to other parts of the body, it is called advanced or metastatic CRC. Some people with CRC have the G12D mutation in the KRAS protein. This mutation is linked to a poorer outlook and fewer treatment options. Currently, there are no approved treatments that specifically target this mutation.

KRAS is a protein that helps control how cells grow and divide. When it is mutated, it can cause cells to grow uncontrollably, leading to cancer. The study drug, BAY 3771249, is designed to block the activity of KRAS with G12D mutation, which may help slow or stop the growth of cancer cells. BAY 3771249 can be given alone or together with another drug called cetuximab.

The main purpose of this study is to learn how safe BAY 3771249 is, how well people tolerate it, how the body processes the drug, and whether it can help shrink or control tumors in people with advanced or metastatic CRC that has the KRAS G12D mutation. The study will also look at how BAY 3771249 works when given alone or with cetuximab, especially in people who have already tried other treatments for their cancer.

Researchers will measure, among others:

The number and seriousness of health problems (adverse events) after receiving BAY 3771249.

The number of participants who experience a dose-limiting side effect (DLT) at each dose level.

The number of participants whose tumors shrink or disappear (overall response rate, ORR) as measured by standard criteria.

How much of the drug is in the blood over time (AUC) and the highest amount in the blood (Cmax).

Some participants will receive BAY 3771249 alone (monotherapy), and others will receive BAY 3771249 with cetuximab (combination therapy).

The study will start with lower doses and gradually increase to find the highest safe dose (dosage escalation). After the safe dose is found, more participants may join the study to receive it (dosage expansion). In some parts of the study, participants may be randomly assigned to different groups or doses. The study is open-label, meaning both participants and doctors know which treatment is being given.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, even if they do not think it is related to the study treatment.

The study doctors and their team will contact participants to learn about their health until they complete the study.

If a participant benefits from the treatment, it might be possible to continue receiving BAY 3771249 after the end of the study. The findings from this study may help develop a new treatment option for people with advanced or metastatic CRC with a KRAS G12D mutation.

The 2 groups in the trial

  • Dosage escalationTreatment being tested

    In the dosage escalation part, different dose levels of BAY 3771249 administered as monotherapy and in combination with cetuximab are planned.

    Treatment: BAY 3771249 and Cetuximab

  • Dosage expansionTreatment being tested

    In the dosage expansion part, participants will receive BAY 3771249 either as monotherapy or in combination with cetuximab until disease progression as defined by RECIST v1.1, the occurrence of unacceptable toxicity, or the fulfillment of any other withdrawal criteria.

    Treatment: BAY 3771249 and Cetuximab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
Master Protocol: An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BAY 3771249 as Monotherapy or Combination With Other Cancer Treatments in Participants With Solid Tumors Harboring a KRAS G12D Mutation. Substudy Protocol: An Open-label, Multi-cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of BAY 3771249 as Monotherapy and in Combination With Cetuximab in Participants With Advanced/Metastatic Colorectal Adenocarcinoma Harboring a KRAS G12D Mutation
Plain-language title
Tests BAY 3771249, alone or with cetuximab, in advanced colorectal cancer with KRAS G12DGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
5 October 2026